RT Journal Article
SR Electronic
T1 Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20072611
DO 10.1101/2020.04.24.20072611
A1 Xiaolong Qi
A1 Yanna Liu
A1 Jonathan A. Fallowfield
A1 Jitao Wang
A1 Jianwen Wang
A1 Xinyu Li
A1 Jindong Shi
A1 Hongqiu Pan
A1 Shengqiang Zou
A1 Hongguang Zhang
A1 Zhenhuai Chen
A1 Fujian Li
A1 Yan Luo
A1 Mei Mei
A1 Huiling Liu
A1 Zhengyan Wang
A1 Jinlin Li
A1 Hua Yang
A1 Huihua Xiang
A1 Xiaodan Li
A1 Tao Liu
A1 Ming-Hua Zheng
A1 Chuan Liu
A1 Yifei Huang
A1 Dan Xu
A1 Xiaoguo Li
A1 Ning Kang
A1 Qing He
A1 Ye Gu
A1 Guo Zhang
A1 Chuxiao Shao
A1 Dengxiang Liu
A1 Lin Zhang
A1 Xun Li
A1 Norifumi Kawada
A1 Zicheng Jiang
A1 Fengmei Wang
A1 Bin Xiong
A1 Tetsuo Takehara
A1 Don C. Rockey
A1 for the COVID-Cirrhosis-CHESS Group
YR 2020
UL http://medrxiv.org/content/early/2020/04/28/2020.04.24.20072611.abstract
AB Background Patients with pre-existing cirrhosis are considered at increased risk of severe coronavirus disease 2019 (COVID-19) but the clinical course in these patients has not yet been reported. This study aimed to provide a detailed report of the clinical characteristics and outcomes among COVID-19 patients with pre-existing cirrhosis.Methods In this retrospective, multicenter cohort study, we consecutively included all adult inpatients with laboratory-confirmed COVID-19 and pre-existing cirrhosis that had been discharged or had died by 24 March 2020 from 16 designated hospitals in China.Demographic, clinical, laboratory and radiographic findings on admission, treatment, complications during hospitalization and clinical outcomes were collected and compared between survivors and non-survivors.Findings Twenty-one patients were included consecutively in this study, of whom 16 were cured and 5 died in hospital. Seventeen patients had compensated cirrhosis and hepatitis B virus infection was the most common etiology. Lymphocyte and platelet counts were lower, and direct bilirubin levels were higher in patients who died than those who survived (p= 0·040, 0·032, and 0·006, respectively). Acute respiratory distress syndrome and secondary infection were both the most frequently observed complications. Only one patient developed acute on chronic liver failure. Of the 5 non-survivors, all patients developed acute respiratory distress syndrome and 2 patients progressed to multiple organ dysfunction syndrome.Interpretation Lower lymphocyte and platelet counts, and higher direct bilirubin level might represent poor prognostic indicators in SARS-CoV-2-infected patients with pre-existing cirrhosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04329559Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI confirm the availability of all data referred to in the manuscript